Deliver Your News to the World

Small BioPharma Poised for Big Turnaround, (OTC:ACCP), (AMEX:HEB)


StocksHaven Investments news portal takes a closer look at Access Pharmaceuticals (OTC:ACCP), which looks ahead for a very successful year with MuGard and their multi-national product distribution deals and partnerships.

Note: StocksHaven Investments is up 121% from the initial buy on May/8/09 of(AMEX:HEB)

Access Pharmaceuticals (OTC:ACCP), a once struggling and troubled company, Access has put these issues behind them and is emerging as one of the top undervalued players in the BioPharma industry. Not only does this company have products which target a large and extensive market, but they are also implementing solid fundamentals within business management principals.

Among other things is a favourable stock price, management and board are significant shareholders (4.53M), and a low number of outstanding shares (21.9M), of these 11.3M common, 10.6M preferred which will be converted to common. Thus the market cap on Yahoo / Google finance is greatly understated by approximately 50%, as at $2 PPS it should be roughly $44M. This certainly shows belief in the future outlook of the potential revenue from their products rather than dilution. StocksHaven Investments believes they are poised for a turnaround and will soon see fit on the Nasdaq and AMEX exchanges. Moreover, Griffin Securities has given Access a 12-month target PPS of $7.50, and it has received the maximum possible Buy Rating from Reuters.

The full special report on the company appears today at

Disclosure: New Position


About StocksHaven Investments

StocksHaven Investments can be found at It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, discussion forum, investment dictionary, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers PR relations and contracting services.

For more financial and investment news, visit


Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.


 access pharma mugard
 mugard product launch
 mugard national product

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.